Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, March 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 79 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 11 publications that cite this research output.

11

The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.

Treatment Costs and Social Burden of Pancreatic Cancer

Article in Cancers (March 2023)

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer

Article in JNCI Cancer Spectrum (June 2022)

Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis

Article in Frontiers in Public Health (April 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.